The lancet oncology

The most recent articles from: Lancet Oncol.

The lancet oncology · Apr 2016

Comment Letter

Carfilozomib versus bortezomib for relapsed or refractory myeloma.

no abstract available

expand abstract… or not…
The lancet oncology · Apr 2016

Multitarget pharmacological inhibition for renal cell carcinoma.

no abstract available

keep going… or not…
The lancet oncology · Apr 2016

Comment Letter

Hyperbaric oxygen therapy for chronic bowel dysfunction after pelvic radiotherapy.

no abstract available

keep going… mark as read…
The lancet oncology · Apr 2016

Comment Letter

Watch-and-wait versus surgical resection for patients with rectal cancer.

no abstract available

explore more… or not…
The lancet oncology · Mar 2016

Randomized Controlled Trial Multicenter Study Comparative Study

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.

Non-clear cell renal cell carcinomas are histologically and genetically diverse kidney cancers with variable prognoses, and their optimum initial treatment is unknown. We aimed to compare the mTOR inhibitor everolimus and the VEGF receptor inhibitor sunitinib in patients with non-clear cell renal cell carcinoma. ⋯ Novartis and Pfizer.

keep reading… or just mark as read…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,694,794 articles already indexed!